A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma

Trial ID or NCT#

NCT06007690

Status

recruiting iconRECRUITING

Purpose

The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma (CM).

Official Title

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma

Eligibility Criteria

Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

Prithvi Mruthyunjaya, MD, MHS
Prithvi Mruthyunjaya, MD, MHS
Ophthalmologic oncologist, Retina specialist, Ophthalmologist
Professor of Ophthalmology and, by courtesy, of Radiation Oncology

Contact us to find out if this trial is right for you.

Contact

Naz Jehangir

SEND MESSAGE

View on ClinicalTrials.gov